Biogen Statistics
Biogen (1BIIB) Stock Statistics & Valuation Metrics
Total Valuation
Biogen has a market cap or net worth of EUR 33.86B. The enterprise value is EUR 39.88B.
- Market Cap
- EUR 33.86B
- Enterprise Value
- EUR 39.88B
Share Statistics
Biogen has 147,820,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 147,820,220
- Owned by Insiders
- 0.18%
- Owned by Institutions
- 72.80%
Financial Efficiency
Biogen’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 6.62%.
- Return on Equity (ROE)
- 0.07
- Return on Assets (ROA)
- 0.04
- Return on Invested Capital (ROIC)
- 6.62%
- Return on Capital Employed (ROCE)
- 0.07
- Revenue Per Employee
- 1.31M
- Profits Per Employee
- 172.45K
- Employee Count
- 7,500
- Asset Turnover
- 0.33
- Inventory Turnover
- 1.34
Valuation Ratios
The current PE Ratio of Biogen is 106.69. Biogen’s PEG ratio is -1.36.
- PE Ratio
- 106.69
- PS Ratio
- 3.61
- PB Ratio
- 1.97
- Price to FCF
- 18.12
- Price to Operating Cash Flow
- 16.56
- PEG Ratio
- -1.36
Income Statement
In the last 12 months, Biogen had revenue of 9.81B and earned 1.29B in profits. Earnings per share was 8.85.
- Revenue
- 9.81B
- Gross Profit
- 6.91B
- Operating Income
- 1.88B
- Pretax Income
- 1.40B
- Net Income
- 1.29B
- EBITDA
- 2.95B
- Earnings Per Share (EPS)
- 8.85
Cash Flow
In the last 12 months, operating cash flow was 2.25B and capital expenditures -192.70M, giving a free cash flow of 2.05B billion.
- Operating Cash Flow
- 2.25B
- Free Cash Flow
- 2.05B
- Free Cash Flow per Share
- 13.90
Dividends & Yields
Biogen pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 5.54%
- Earnings Yield
- 0.94%
Stock Price Statistics
- Beta
- 0.30
- 52-Week Price Change
- 63.98%
- 50-Day Moving Average
- 204.40
- 200-Day Moving Average
- 177.68
- Relative Strength Index (RSI)
- 62.07
- Average Volume (3m)
- 56
Important Dates
Biogen upcoming earnings date is Feb 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 28, 2026
- Next Earnings Date
- Feb 17, 2027
- Ex-Dividend Date
- ―
Financial Position
Biogen as a current ratio of 2.68, with Debt / Equity ratio of 38.06%
- Current Ratio
- 2.68
- Quick Ratio
- 2.03
- Debt to Market Cap
- 0.26
- Net Debt to EBITDA
- 1.34
- Interest Coverage Ratio
- 7.63
Taxes
In the past 12 months, Biogen has paid 108.11M in taxes.
- Income Tax
- 108.11M
- Effective Tax Rate
- 0.08
Enterprise Valuation
Biogen EV to EBITDA ratio is 30.09, with an EV/FCF ratio of 21.21.
- EV to Sales
- 4.23
- EV to EBITDA
- 30.09
- EV to Free Cash Flow
- 21.21
- EV to Operating Cash Flow
- 19.39
Balance Sheet
Biogen has EUR 1.30B in cash and marketable securities with EUR 7.80B in debt, giving a net cash position of -EUR 6.50B billion.
- Cash & Marketable Securities
- EUR 1.30B
- Total Debt
- EUR 7.80B
- Net Cash
- -EUR 6.50B
- Net Cash Per Share
- -EUR 43.95
- Tangible Book Value Per Share
- -EUR 9.81
Margins
Gross margin is 70.05%, with operating margin of 7.64%, and net profit margin of 3.38%.
- Gross Margin
- 70.05%
- Operating Margin
- 7.64%
- Pretax Margin
- 2.82%
- Net Profit Margin
- 3.38%
- EBITDA Margin
- 14.07%
- EBIT Margin
- 5.50%
Analyst Forecast
The average price target for Biogen is EUR 239.47, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 239.47
- Price Target Upside
- 4.80% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 25
- Revenue Growth Forecast
- -2.84%
- EPS Growth Forecast
- -79.49%
Scores
- Smart Score
- 9
- AI Score
- ―
